-
Feb.012023NEWS
HanAll Biopharma Reports Full-Year 2022 Results and Provides..
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
-
Nov.162022NEWS
HanAll Biopharma Reports Third Quarter 2022 Results and Prov..
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
-
Oct.112022NEWS
HanAll’s Licensed Partner in China Enters Sublicense Agreeme..
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Devel..
-
Oct.112022NOTICE
HanAll Biopharma’s Licensed Partner in China Provides Update..
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in..
-
Oct.052022NEWS
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the D..
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partn..
-
Jul.292022NEWS
HanAll Biopharma Reports Second Quarter 2022 Results and Pro..
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update